Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research ...( - Data Support Intravenous ...),Health

- Data Support Intravenous to Subcutaneous Conversion -

SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical findings on the local tolerability and pharmacokinetics of bisphosphonates combined with rHuPH20 at the American Association for Cancer Research (AACR) conference.

The objectives of the presented studies were to investigate in animal models whether increasing the dispersion and absorption of bisphosphonates in the skin and subcutaneous tissues with rHuPH20 could modify injection site reaction (ISR) profiles from two intravenous bisphosphonate formulations, zoledronic acid and ibandronate. The pharmacokinetics of bisphosphonates in blood were also examined and compared to intravenous infusion. Key findings from the study were as follows:

-- In rodent intradermal models, injection of bisphosphonates without

rHuPH20 created injection site reactions characterized by erythema,

induration, and ulceration in a concentration dependent manner.

-- In rodent intradermal models, the maximal concentration of

bisphosphonates that could be administered without producing ISRs was

increased 3- to 5-fold when co-administered in combination with

rHuPH20.

-- In porcine pharmacokinetic models, absolute bioavailability by

subcutaneous (SC) injection with rHuPH20 was comparable to IV

infusion.

"Historically, hyaluronidase products have been utilized as an antidote to local extravasations of certain chemotherapy agents," said Gregory Frost, PhD, Halozyme's Vice
'/>"/>